GlassScriptPhysician profile
Kishore Sehgal
NPI 1689671034
$15,068.53
in general payments reported to CMS, 2019-2025
77 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $397 · 2021: $1,778 · 2022: $2,363 · 2023: $2,915 · 2024: $3,142 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,549 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,548.88 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $191.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,489.34 | 2019-2025 | |
| Janssen Biotech, INC. | $1,536.23 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $964.98 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Pfizer INC. | $595.77 | 2019-2025 | |
| Seagen INC. | $565.80 | 2019-2023 | Adcetris, Padcev, Tivdak |
| Merck Sharp & Dohme LLC | $440.97 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $427.01 | 2019-2025 | Venclexta, Dalvance |
| Incyte Corporation | $411.14 | 2019-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $366.11 | 2019-2025 | Opdualag, Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $360.01 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Amgen INC. | $351.60 | 2019-2025 | Lumakras |
| Genzyme Corporation | $324.33 | 2021-2025 | |
| Astellas Pharma US INC | $299.03 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $271.29 | 2019-2022 | |
| Sobi, INC | $262.54 | 2022-2025 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $244.49 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $232.61 | 2021-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $220.92 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Jazz Pharmaceuticals INC. | $219.36 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $215.04 | 2022-2025 | Xpovio |
| Celgene Corporation | $211.24 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Array Biopharma INC | $203.37 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Coherus Oncology, INC. | $191.27 | 2022-2025 | Loqtorzi, Udenyca |
| Genentech USA, INC. | $185.61 | 2019-2025 | Kadcyla, Tecentriq, Phesgo |
| Gilead Sciences, INC. | $174.44 | 2019-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $169.96 | 2021-2025 | Libtayo, Lynozyfic |
| Epizyme, INC. | $165.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.74 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $142.99 | 2019-2025 | Provenge |
| Beigene USA, INC. | $142.91 | 2021-2025 | Tevimbra, Brukinsa |
| Rigel Pharmaceuticals, INC. | $140.43 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $134.62 | 2019-2024 | Ninlaro, Alunbrig, Fruzaqla |
| Lilly USA, LLC | $131.08 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Ipsen Biopharmaceuticals, INC | $130.25 | 2021-2025 | Onivyde, Tazverik |
| Puma Biotechnology, INC. | $113.11 | 2023-2025 | Nerlynx |
| Stemline Therapeutics INC. | $105.38 | 2019-2023 | Orserdu |
| Intuitive Surgical, INC. | $105.24 | 2019 | |
| Verity Pharmaceuticals INC. | $81.99 | 2022-2025 | Trelstar |
| Taiho Oncology, INC. | $79.76 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $74.03 | 2022-2024 | Clonoseq |
| Accord Healthcare, INC. | $73.35 | 2023 | |
| Blueprint Medicines Corporation | $67.23 | 2023-2024 | Ayvakit |
| Fennec Pharmaceuticals, INC. | $65.66 | 2025 | Fyarro |
| Octapharma USA, INC. | $65.32 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Genmab U.S., INC. | $63.96 | 2025 | Epkinly |
| Beone Medicines USA, INC. | $57.57 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $55.64 | 2020-2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $53.75 | 2023 | Monoferric |
| Organon LLC | $52.55 | 2022 | |
| Eusa Pharma (US) LLC | $47.95 | 2019-2021 | |
| Mylan Institutional INC. | $47.71 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $47.28 | 2021-2025 | |
| Tg Therapeutics, INC. | $45.86 | 2021 | |
| Springworks Therapeutics, INC. | $44.99 | 2024 | Ogsiveo |
| Servier Pharmaceuticals LLC | $44.11 | 2022-2023 | |
| Kite Pharma, INC. | $42.75 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $40.13 | 2021-2022 | |
| Emd Serono, INC. | $39.70 | 2023-2024 | Bavencio |
| Janssen Pharmaceuticals, INC | $38.32 | 2022-2025 | |
| Mirati Therapeutics, INC. | $37.77 | 2023 | Krazati |
| Myovant Sciences INC. | $34.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.64 | 2021 | |
| Acrotech Biopharma INC. | $32.23 | 2021-2023 | Beleodaq |
| Exelixis INC. | $31.42 | 2025 | Cabometyx |
| Tempus Ai, INC | $27.02 | 2024 | |
| Apellis Pharmaceuticals, INC. | $25.21 | 2023 | Empaveli |
| Legend Biotech USA INC. | $24.52 | 2025 | Carvykti |
| Immunocore Limited | $24.00 | 2024 | Kimmtrak |
| Sanofi-Aventis U.S. LLC | $22.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.84 | 2022 | |
| Morphosys, US INC. | $22.81 | 2021 | |
| Aurobindo Pharma USA, INC. | $22.68 | 2019 | |
| Recordati_rare_diseases_inc. | $21.29 | 2023 | Sylvant |
| Sirtex Medical INC | $20.06 | 2023 | Sir-Spheres Microspheres |
| Secura Bio, INC. | $16.21 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.32 | 2025 | Danziten |
| Mayne Pharma Commercial LLC | $12.93 | 2022 |
Drugs and devices associated with these payments
Kisqali $1,583Erleada $321Darzalex $286Lynparza $279Keytruda $269Adcetris $244Tecvayli $241Jakafi $240Scemblix $211Welireg $195Imbruvica $194Xpovio $190Doptelet $185Ultomiris $182Calquence $177Elrexfio $168Braftovi $161Mektovi $161Udenyca $143Tukysa $141Sarclisa $141Xtandi $140Enhertu $138Ibrance $129Epkinly $123Provenge $118Reblozyl $115Pomalyst $98.02Carvykti $91.00Imfinzi $87.10Pluvicto $86.96Opdualag $85.88Lutathera $85.40Piqray $80.33Xalkori $80.03Lorbrena $80.03Bosulif $78.71Libtayo $77.17Venclexta $76.23Loqtorzi $75.70Vitrakvi $74.12Stivarga $74.12Camcevi $73.35Lenvima $73.28Brukinsa $71.98Nerlynx $69.90Ayvakit $67.23Fyarro $65.66Kadcyla $64.64Tecentriq $64.64Phesgo $64.64Elahere $62.98Trelstar $62.67Talvey $62.48Lonsurf $60.94Inqovi $60.94Paxlovid $59.55Trodelvy $59.12Ojjaara $58.85Itovebi $55.50Talzenna $55.06Monoferric $53.75Padcev $52.44Nubeqa $52.41Inlyta $51.99Onivyde $50.76Ninlaro $50.67Balversa $50.30Akeega $50.30Jaypirca $49.97Retevmo $49.97Bavencio $48.80Clonoseq $47.65Rezlidhia $46.53Tavalisse $46.53Panzyga $46.32Ogsiveo $44.99Mekinist $42.60Opdivo $40.49Orserdu $39.69Pyrukynd $38.33Krazati $37.77Alunbrig $34.39Perjeta $34.23Monjuvi $32.43Vyloy $31.61Vanflyta $31.58Cabometyx $31.42Tevimbra $30.60Zejula $30.41Alecensa $30.41Rozlytrek $30.41Jemperli $30.41Tivdak $30.29Besponsa $29.68Orgovyx $29.14Datroway $28.35Lynozyfic $27.64Lupron Depot $27.07Fabhalta $26.95
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishore Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.